- 501 Orchard Road, #04-08 Wheelock Place, Singapore 238880
- (65) 6235 4429
- hello@vidaskinclinic.com
- (65) 9830 0597
Under-eye fillers can soften a tear-trough hollow and improve the transition between the lower eyelid and cheek in carefully selected patients. The area also requires caution because the skin is thin, fluid retention is common, and even a small amount of product can create a visible change.
A satisfactory result depends on appropriate candidate selection, a clear understanding of the anatomy, and conservative volume. It is also important to identify the cause of the under-eye concern, as dark pigmentation, visible blood vessels, thin skin, and prominent eye bags will not improve with filler in the same way as true under-eye hollowness.
Several anatomical features make the under-eye less forgiving than many other filler sites.
The lower eyelid has some of the thinnest skin on the body and very little subcutaneous padding. Products that are well concealed in a fuller facial area may be visible here as either an irregular contour or a colour change.
Safe filler treatment requires a clear understanding of facial anatomy, including the location of blood vessels and the correct depth for injection.[1] This is especially important in the periorbital region, where small differences in depth or volume may be noticeable.
The infraorbital area is prone to fluid retention, so swelling can be more persistent here than in some other treatment areas. Published technique literature discusses infraorbital adverse effects and their management, including measures intended to reduce post-treatment oedema.
Early puffiness should be allowed to settle before the final result is assessed. Adding more product during this period may overcorrect an area that is still temporarily swollen.
Cadaveric volumetric research found that facial fat compartments respond differently when volume is added. The sub-orbicularis oculi fat compartment showed one of the highest surface-volume coefficients in the analysis.
This means that a relatively small volume in the under-eye region may produce a noticeable surface change. Conservative treatment and planned review are therefore particularly important.
Treatment outcomes are more predictable when the patient’s concern matches what filler is designed to address.
Filler may be suitable where a genuine hollow or groove creates a structural shadow. Restoring part of that contour can reduce the shadow and soften the under-eye appearance.
It may also improve an abrupt transition between the lower eyelid and cheek where age-related volume change is contributing to a tired appearance.
Filler does not treat melanin within the skin, so it will not correct predominantly pigmentary dark circles.
It also does not remove visible vessels, significant excess eyelid skin, or prolapsed orbital fat. Superficial placement can accentuate a blue-grey appearance, while adding volume around a prominent fat pad may make an eye bag look fuller.
Where volume deficiency and reduced skin quality occur together, addressing only one component may provide incomplete improvement. Combined approaches have therefore been described for selected patients.
All injectable treatments carry risk. Discussing the relevant complications allows patients to make an informed decision and recognise when review is needed.
Persistent puffiness is a common reason for dissatisfaction after under-eye filler. It may be influenced by product properties, treatment volume, placement depth and the patient’s tendency to retain fluid in this area. Published technique guidance addresses prevention and management of infraorbital oedema.
When swelling is being maintained by excess or poorly positioned product, reducing or removing the product may be more appropriate than waiting without reassessment.
Product placed too superficially may appear as a palpable or visible irregularity. It can also create a blue-grey cast through thin skin because of the way light scatters. Superficial nodularity in the infraorbital hollow has been reported, including with non-hyaluronic-acid products.
This is one reason hyaluronic acid is commonly preferred to permanent or semi-permanent products in this region: if an HA-related irregularity occurs, the product can be reduced with hyaluronidase.
The most serious filler complication is inadvertent injection into, or compression of, a blood vessel. Published cases also highlight that vascular occlusion can occur even with small amounts of filler, making early recognition and prompt treatment with hyaluronidase essential.
Although vascular occlusion is uncommon, patients can reasonably ask whether hyaluronidase is available and how the clinic would manage an urgent complication. The treating clinician’s anatomical knowledge and emergency preparedness are important parts of safe care.
Hyaluronidase is an enzyme that breaks down hyaluronic acid. It may be used electively to reduce an unsatisfactory HA filler result and urgently as part of the management of a suspected vascular event.
Hyaluronidase also has its own risks, including hypersensitivity reactions, and its use for dissolving filler is off-label in many jurisdictions. It is a medical treatment that requires appropriate assessment and consent.
In a visible and technically demanding area such as the under-eye, the ability to reduce an HA filler result is an important safety consideration rather than simply a matter of convenience.
Candidate selection has a major influence on both the potential benefit and the risk of treatment.
Under-eye filler may be considered for patients with:
Treatment may be unsuitable, or require additional caution, where there is:
A recommendation not to proceed can be an appropriate outcome of consultation. It indicates that the expected benefit does not justify the limitations or risks for that particular anatomy.
Before treatment, patients may wish to ask:
Medical devices supplied in Singapore are regulated by the Health Sciences Authority according to risk classification.[9] The Singapore Medical Council also places particular emphasis on informed consent in aesthetic practice, including discussion of relevant risks.[10] A doctor’s registration can be checked through the Ministry of Health’s public register.[11]
The under-eye area generally benefits from a conservative approach. Treatment can begin with a small volume, followed by adequate time for swelling to settle and a review before any further adjustment is considered.
At VIDASKIN, assessment first determines whether the appearance is primarily due to structural shadowing, pigmentation, visible vessels, skin quality, fluid retention, or a combination. Filler is considered only where volume restoration is likely to address the relevant component.
To learn more or book a consultation, visit or contact us today.
Some early swelling is expected because the infraorbital region readily retains fluid. Puffiness that persists may relate to product volume, placement depth, or individual anatomy. Where the product is contributing, clinical review can determine whether reduction is appropriate.
Hyaluronic acid filler can be reduced with hyaluronidase, which is one reason it is commonly selected over permanent products for the under-eye area. Hyaluronidase has its own risks, including hypersensitivity, and should be administered by a doctor following assessment.
